References
1. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med . Sep 10 2020;383(11):1085-1087. doi:10.1056/NEJMc2025179
2. Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci Immunol . Jul 17 2020;5(49)doi:10.1126/sciimmunol.abd6160
3. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell . Jun 25 2020;181(7):1489-1501 e15. doi:10.1016/j.cell.2020.05.015
4. Sette A, Crotty S. Author Correction: Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat Rev Immunol . Oct 2020;20(10):644. doi:10.1038/s41577-020-00430-w
5. Riou C, Schafer G, du Bruyn E, et al. Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2 specific T cells. Eur Respir J . Jun 17 2021;doi:10.1183/13993003.00285-2021
6. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.Nature . Aug 2020;584(7821):457-462. doi:10.1038/s41586-020-2550-z
7. Zuo J, Dowell AC, Pearce H, et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection.Nature Immunology . 2021/05/01 2021;22(5):620-626. doi:10.1038/s41590-021-00902-8
8. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science . Feb 5 2021;371(6529)doi:10.1126/science.abf4063
9. Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. J Clin Invest . May 17 2021;131(10)doi:10.1172/jci149335
10. Sewell HF, Agius RM, Kendrick D, Stewart M. Covid-19 vaccines: delivering protective immunity. BMJ . Dec 17 2020;371:m4838. doi:10.1136/bmj.m4838
11. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine . 2021/02/01 2021;27(2):270-278. doi:10.1038/s41591-020-01194-5
12. Sahin U, Muik A, Derhovanessian E, et al. Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature . Feb 2021;590(7844):E17. doi:10.1038/s41586-020-03102-w
13. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J . Jan 2011;37(1):88-99. doi:10.1183/09031936.00115110
14. Murugesan K, Jagannathan P, Pham TD, et al. Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response. Clin Infect Dis . Oct 9 2020;doi:10.1093/cid/ciaa1537
15. Petrone L, Petruccioli E, Vanini V, et al. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin Microbiol Infect . Feb 2021;27(2):286 e7-286 e13. doi:10.1016/j.cmi.2020.09.051
16. Youden WJ. Index for rating diagnostic tests. Cancer . Jan 1950;3(1):32-5. doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
17. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J . Aug 2005;47(4):458-72. doi:10.1002/bimj.200410135
18. Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet . Mar 27 2021;397(10280):1178-1181. doi:10.1016/S0140-6736(21)00502-X
19. Reynolds CJ, Pade C, Gibbons JM, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose.Science . Apr 30 2021;doi:10.1126/science.abh1282
20. Rabaan AA, Al-Ahmed SH, Haque S, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez Med . Ahead Of Print Jun 1 2020;28(2):174-184.
21. Payne DC, Iblan I, Rha B, et al. Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus. Emerg Infect Dis . Oct 2016;22(10):1824-6. doi:10.3201/eid2210.160706
22. Wu LP, Wang NC, Chang YH, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis . Oct 2007;13(10):1562-4. doi:10.3201/eid1310.070576
23. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science . Dec 4 2020;370(6521):1227-1230. doi:10.1126/science.abd7728